Answers are grounded in this paper and cite their sources.
Case report details clinical efficacy of pembrolizumab and surgical treatment for undifferentiated pleomorphic sarcoma, suggesting potential for improved prognosis.
Undifferentiated pleomorphic sarcoma of the liver (UPSL) is a rare pathological type characterized by an undefined mechanism, low incidence, high metastatic rate, aggressive behavior, and an inferior prognosis; no standardized treatment protocols or guidelines currently exist. This article reports the case of an 83-year-old male with UPSL confirmed through surgical resection and pathological biopsy. Postoperatively, he received eight cycles of pembrolizumab, which resulted in a favorable clinical efficacy. With advances in medical technology, the integration of surgery and immunotherapy is expected to play an essential role in treating this rare disease and monitoring its prognosis.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: